PANews reported on October 21st that NewLimit, a longevity research company co-founded by Coinbase's CEO, retweeted a message from co-founder Jacob Kimmel stating that NewLimit has secured $45 million in additional funding from investors including Lilly Ventures, Duke University, S32, and Abstract, with participation from new and existing shareholders such as Kleiner Perkins, Dimension, Human Capital, and Boost VC. This round of financing stems from a technological breakthrough in their project to restore youthful liver function, with plans to initiate clinical studies in the coming years.
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.